share_log

普蕊斯(301257.SZ):截至2023年12月公司已累计推动61个肿瘤新药和11个肿瘤生物类似药或化学仿制药产品在国内外上市

Prius (301257.SZ): As of December 2023, the company has promoted the listing of 61 new oncology drugs and 11 tumor biosimilar or chemical generic products at home and abroad

Gelonghui Finance ·  May 9 06:15

Glonghui, May 9 | Prius (301257.SZ) said on the investor interactive platform that by the end of March 2024, the company had undertaken more than 3,100 international and domestic clinical projects and participated in many popular domestic and foreign projects. The service can cover 24 fields such as hematological tumors, thoracic tumors, digestive tumors, urinary tumors, rare diseases, etc., and has a great competitive advantage in various disease segments such as hematological tumors, thoracic tumors, digestive tumors, cardiovascular diseases, and urological tumors. In the field of oncology, as of December 2023, the company has promoted the listing of 61 new oncology drugs and 11 tumor biosimilar or chemical generic products at home and abroad. In addition, the company also undertakes clinical trial projects for ICU-related severe cases.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment